 BOSTON--BUSINESS WIRE--Gamida Cell Ltd. Nasdaq: GMDA, an advanced cell therapy company committed to cures for cancer and other serious diseases, today reported financial results for the quarter ended June 30, 2021. Net loss for the second quarter of 2021 was 21.3 million, compared to a net loss of 15.1 million for the same period in 2020. As of June 30, 2021, Gamida Cell had total cash and cash equivalents of 150.2 million. During the quarter, the company continued to execute on plans to 